Post-Test Innovations in Vascular Access Creation and Maintenance: What the Nephrologist Needs to Know Post-Test This is attempt (1/3) 1. Upper extremity ___________ should be assessed for suitability with ultrasound before percutaneous AVF procedures. a. Musculature b. Vasculature c. Tissue integrity d. Flexibility 2. __________ is the current drug approved for AV access. a. Methotrexate b. Pralatrexate c. Paclitaxel d. Doxorubicin 3. Ultrasound is used in a variety of hemodialysis access applications, including: a. Preoperative vascular mapping b. Cannulation c. Access maintenance surveillance d. All of the above 4. Ultrasound should complement physical examination as an adjunct, not a replacement. a. True b. False 5. Drug-coated balloon angioplasty is superior to plain balloon angioplasty in maintaining target lesion primary and ________ patency among patients with dialysis circuit stenosis. a. Secondary b. Tertiary c. Circuit d. Circular 6. End-stage kidney disease patients participating in the IN.PACT AV Access IDE study had a median time to reintervention that was ____ months longer when treated with drug-coated balloons compared to percutaneous transluminal angioplasty. a. 6.5 b. 10.2 c. 14.7 d. 16.4 7. The practice of evidence-based medicine means integrating individual clinical expertise with the best available external clinical evidence. a. True b. False 8. When considering which access method for each patient, consider each of the following except: a. Age b. Risk of dialysis c. Preference d. BMI Previous
